(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that the Company’s poster entitled: CAR-T Cells Harboring Camelid Single Domain Antibody as Targeting Agent to CEACAM6 Antigen in Pancreatic Cancer has been accepted for presentation at the AACR Conference on Tumor Immunology and Immunotherapy taking place on October 20th through to the 23rd, 2016 at the Boston Marriott Copley Place in Boston, Massachusetts.
- 0 Comments
- FY2017